Low Dose of Valproate Improves Motor Function after Traumatic Brain Injury
Open Access
- 1 January 2014
- journal article
- research article
- Published by Wiley in BioMed Research International
- Vol. 2014, 1-8
Abstract
Background.Traumatic brain injuries (TBIs) are a major health care problem worldwide. Approximately 1.5 million new TBI cases occur annually in the United States, with mortality rates ranging between 35% and 40% in severe patients. Despite the incidence of these injuries and their substantial socioeconomic implications, no specific pharmacological intervention is available for clinical use. Several studies have indicated that 300 mg/kg or 400 mg/kg of valproate (VPA) exhibits neuroprotective effects in animal models. However, humans cannot tolerate high doses of VPA. This study aims to investigate whether 30 mg/kg of VPA administered to rats affects TBIs.Methods.We used a rat model to test the effects of 30 mg/kg of VPA on TBIs. Molecular identifications for histone acetylation and phosphorylation of cAMP response element-binding protein (CREB) and phosphorylated extracellular signal regulated kinase (ERK) were performed.Results.The results indicated that treating adult rats with VPA after TBIs significantly decreased the contusion volume and recovery of contusion-related skilled forelimb reaching deficits. Applying VPA also increased histone acetylation, p-ERK, and p-CREB expression in the brain. Furthermore, applying VPA reduced inflammation, glial fibrillary acidic protein activation, and apoptosis.Conclusion.This study found that 30 mg/kg of VPA assists in treating TBIs in rat models.Keywords
Funding Information
- National Science Council (NSC 99-2314-B-038-004-MY3, NSC 102-2321-B-038-003, NSC 99-2323-B-038-003, DOH101-TD-B-111-003)
- National Science Council (NSC 99-2314-B-038-004-MY3, NSC 102-2321-B-038-003, NSC 99-2323-B-038-003, DOH101-TD-B-111-003)
- National Science Council (NSC 99-2314-B-038-004-MY3, NSC 102-2321-B-038-003, NSC 99-2323-B-038-003, DOH101-TD-B-111-003)
- Center of Excellence for Clinical Trial and Research in Neuroscience from the Department of Health, Taiwan (NSC 99-2314-B-038-004-MY3, NSC 102-2321-B-038-003, NSC 99-2323-B-038-003, DOH101-TD-B-111-003)
This publication has 21 references indexed in Scilit:
- Molecular and Therapeutic Potential and Toxicity of Valproic AcidJournal of Biomedicine and Biotechnology, 2010
- Histone Deacetylase Inhibitors Enhance Memory and Synaptic Plasticity via CREB: CBP-Dependent Transcriptional ActivationThe Journal of Neuroscience, 2007
- Sodium Valproate Exerts Neuroprotective EffectsIn Vivothrough CREB-Binding Protein-Dependent Mechanisms But Does Not Improve Survival in an Amyotrophic Lateral Sclerosis Mouse ModelJournal of Neuroscience, 2007
- Treatment with valproate after status epilepticus: Effect on neuronal damage, epileptogenesis, and behavioral alterations in ratsNeuropharmacology, 2006
- Cell Death Mechanisms Following Traumatic Brain InjuryBrain Pathology, 2004
- Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein inductionJournal of Neurochemistry, 2004
- Bench-to-bedside review: Apoptosis/programmed cell death triggered by traumatic brain injuryCritical Care, 2004
- The Mood Stabilizer Valproic Acid Activates Mitogen-activated Protein Kinases and Promotes Neurite GrowthJournal of Biological Chemistry, 2001
- Valproate therapy for prevention of posttraumatic seizures: a randomized trialJournal of Neurosurgery, 1999
- The Role of Excitatory Amino Acids and NMDA Receptors in Traumatic Brain InjuryScience, 1989